ACCESS Newswire4d agobearish
Moderna Advances Investigational Bundibugyo Ebolavirus Vaccine Toward Phase 2/3 StudyNews
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
108last 24h
3128last 7d
512● bullish (7d)
311● bearish (7d)
227publishers
Clinical Trials Arena90d agoneutral
FDA approval of mFLUSIVA highlights Moderna’s position in mRNA marketThe Wall Street Journal95d agoneutral
FDA Approves First mRNA Flu Vaccine in Win for Moderna After Arduous Review